ID:HCK_HUMAN DESCRIPTION: RecName: Full=Tyrosine-protein kinase HCK; EC=2.7.10.2; AltName: Full=Hematopoietic cell kinase; AltName: Full=Hemopoietic cell kinase; AltName: Full=p59-HCK/p60-HCK; AltName: Full=p59Hck; AltName: Full=p61Hck; FUNCTION: Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS. CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. ENZYME REGULATION: Subject to autoinhibition, mediated by intramolecular interactions involving the SH2 and SH3 domains. Kinase activity is also regulated by phosphorylation at regulatory tyrosine residues. Phosphorylation at Tyr-411 is required for optimal activity. Phosphorylation at Tyr-522 inhibits kinase activity. Inhibited by PP1 and A-770041. SUBUNIT: Interacts (via SH2 domain) with FLT3 (tyrosine phosphorylated). Interacts with VAV1, WAS and RAPGEF1 (By similarity). Interacts (via SH3 domain) with HIV-1 Nef and Vif. This interaction stimulates its tyrosine-kinase activity. Interacts (via SH3 domain) with HEV ORF3 protein. Interacts with ARRB1 and ARRB2. Interacts with ADAM15. Interacts with FASLG. Interacts with CBL. Interacts with FCGR1A; the interaction may be indirect. Interacts with IL6ST. Interacts (via SH3 domain) with ELMO1. Interacts (via SH3 domain) with TP73. Interacts with YAP1. Interacts with ABL1 and ITGB1, and thereby recruits ABL1 to activated ITGB1. INTERACTION: O92972:- (xeno); NbExp=2; IntAct=EBI-346340, EBI-710506; P27958:- (xeno); NbExp=5; IntAct=EBI-346340, EBI-706378; Q92556:ELMO1; NbExp=4; IntAct=EBI-346340, EBI-346417; Q07666:KHDRBS1; NbExp=2; IntAct=EBI-346340, EBI-1364; P12504:vif (xeno); NbExp=3; IntAct=EBI-346340, EBI-779991; P42768:WAS; NbExp=9; IntAct=EBI-346340, EBI-346375; O43516:WIPF1; NbExp=3; IntAct=EBI-346340, EBI-346356; SUBCELLULAR LOCATION: Isoform 1: Lysosome. Membrane; Lipid-anchor. Cell projection, podosome membrane; Lipid-anchor. Cytoplasm, cytosol. Note=Associated with specialized secretory lysosomes called azurophil granules. At least half of this isoform is found in the cytoplasm, some of this fraction is myristoylated. SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Lipid-anchor. Membrane, caveola; Lipid-anchor. Cell junction, focal adhesion. Cytoplasm, cytoskeleton. Golgi apparatus. Cytoplasmic vesicle. Lysosome. Nucleus. Note=20% of this isoform is associated with caveolae. Localization at the cell membrane and at caveolae requires palmitoylation at Cys-3. Colocalizes with the actin cytoskeleton at focal adhesions. SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle. Cytoplasm, cytosol. TISSUE SPECIFICITY: Detected in monocytes and neutrophils (at protein level). Expressed predominantly in cells of the myeloid and B-lymphoid lineages. Highly expressed in granulocytes. Detected in tonsil. INDUCTION: Up-regulated during myeloid cell differentiation. The highest levels are detected in fully differentiated phagocytes. Up-regulated by IL2. DOMAIN: The SH3 domain mediates binding to HIV-1 Nef. PTM: Phosphorylated on serveral tyrosine residues. Autophosphorylated. Becomes rapidly phosphorylated upon activation of the immunoglobulin receptors FCGR1A and FCGR2A. Phosphorylation by the BCR-ABL fusion protein mediates activation of HCK. Phosphorylation at Tyr-411 increases kinase activity. Phosphorylation at Tyr-522 inhibits kinase activity. Kinase activity is not required for phosphorylation at Tyr-522, suggesting that this site is a target of other kinases. PTM: Ubiquitinated by CBL, leading to its degradation via the proteasome. PTM: Isoform 2 palmitoylation at position 2 requires prior myristoylation. Palmitoylation at position 3 is required for caveolar localization of isoform 2. DISEASE: Note=Aberrant activation of HCK by HIV-1 protein Nef enhances HIV-1 replication and contributes to HIV-1 pathogenicity. DISEASE: Note=Aberrant activation of HCK, e.g. by the BCR-ABL fusion protein, promotes cancer cell proliferation. SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily. SIMILARITY: Contains 1 protein kinase domain. SIMILARITY: Contains 1 SH2 domain. SIMILARITY: Contains 1 SH3 domain. SEQUENCE CAUTION: Sequence=AAA52643.1; Type=Frameshift; Positions=20; Sequence=BAF82585.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.
ModBase Predicted Comparative 3D Structure on P08631
Front
Top
Side
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.
Orthologous Genes in Other Species
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
AK289896 - Homo sapiens cDNA FLJ77650 complete cds. AK298726 - Homo sapiens cDNA FLJ60326 complete cds, highly similar to Tyrosine-protein kinase HCK (EC 2.7.10.2). AK225819 - Homo sapiens mRNA for hemopoietic cell kinase isoform p61HCK variant, clone: FCC128H06. AK290928 - Homo sapiens cDNA FLJ78472 complete cds, highly similar to Human hemopoietic cell protein-tyrosine kinase (HCK) gene. AK026432 - Homo sapiens cDNA: FLJ22779 fis, clone KAIA1741. BC108930 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:120509 IMAGE:40025497), complete cds. BC108931 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:120510 IMAGE:40025500), complete cds. BC113854 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:120512 IMAGE:40025503), complete cds. BC114463 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:120511 IMAGE:40025502), complete cds. AK314335 - Homo sapiens cDNA, FLJ95095. BC094847 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:104866 IMAGE:5923744), complete cds. BC014435 - Homo sapiens hemopoietic cell kinase, mRNA (cDNA clone MGC:22922 IMAGE:4855747), complete cds. M16591 - Human hemopoietic cell protein-tyrosine kinase (HCK) gene, complete cds, clone lambda-a2/1a. M16592 - Human hemopoietic cell protein-tyrosine kinase (HCK) gene, complete cds, clone HK24. CU676991 - Synthetic construct Homo sapiens gateway clone IMAGE:100019717 5' read HCK mRNA. KJ891339 - Synthetic construct Homo sapiens clone ccsbBroadEn_00733 HCK gene, encodes complete protein. JD065986 - Sequence 47010 from Patent EP1572962. BC073748 - Homo sapiens cDNA clone IMAGE:6301005, partial cds. JD535703 - Sequence 516727 from Patent EP1572962. JD506843 - Sequence 487867 from Patent EP1572962. JD367959 - Sequence 348983 from Patent EP1572962. JD456202 - Sequence 437226 from Patent EP1572962. JD280746 - Sequence 261770 from Patent EP1572962. JD077577 - Sequence 58601 from Patent EP1572962. JD478745 - Sequence 459769 from Patent EP1572962. JD382166 - Sequence 363190 from Patent EP1572962. JD152019 - Sequence 133043 from Patent EP1572962. JD086659 - Sequence 67683 from Patent EP1572962. JD184525 - Sequence 165549 from Patent EP1572962.
Biochemical and Signaling Pathways
BioCarta from NCI Cancer Genome Anatomy Project h_vifPathway - HIV-1 defeats host-mediated resistance by CEM15 h_bArrestin-srcPathway - Roles of ¿-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling
Reactome (by CSHL, EBI, and GO)
Protein P08631 (Reactome details) participates in the following event(s):